Management of antiviral resistance in patients with chronic hepatitis B.
about
Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutantDetection and analysis of resistance mutations of hepatitis B virusAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?Novel approaches towards conquering hepatitis B virus infection.Antiviral drug resistance as an adaptive processEfficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled studyEfficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistanceComplex dynamics of hepatitis B virus resistance to adefovir.Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.Current status of antiviral therapy for hepatitis BEfficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24.Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR.Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study.HBV and HCV therapy.Management of hepatitis B in developing countries.High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in SingaporeA prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.Assessment of Adherence to Prescribed Therapy in Patients with Chronic Hepatitis B.Future prospectives for the management of chronic hepatitis B.Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.Antiviral resistance and hepatitis B therapy.A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistanceUpdate on rescue therapies in patients with lamivudine-resistant chronic hepatitis BDetectability and clinical significance of serum hepatitis B virus ribonucleic acidViral resistance in hepatitis B: prevalence and management.Management of HBV infection during immunosuppressive treatmentEntecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.Involvement of PUF60 in Transcriptional and Post-transcriptional Regulation of Hepatitis B Virus Pregenomic RNA ExpressionPrimary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failureEvaluation of the Abbott RealTime HBV DNA assay and comparison to the Cobas AmpliPrep/Cobas TaqMan 48 assay in monitoring patients with chronic cases of hepatitis B.Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus.Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine.Clinical management of patients with recurrent viral hepatitis after liver transplantation.New developments in HBV molecular diagnostics and quantitative serology.Current treatment indications and strategies in chronic hepatitis B virus infection.Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology.
P2860
Q25256648-7B153DD8-AB1C-4069-9F56-A3F95731F8FCQ28266666-8C438297-69E5-41FD-955B-D96A42BEEA68Q30391932-6EB0E030-598D-46D9-B5D1-72DD44912266Q33574740-BD3AB416-6FBF-43A2-AFCF-78CBF5206782Q33787687-F851CAD7-B9E9-46A0-9D2A-3CD0F1E2FA25Q33878407-B0D8914B-6F38-4F9F-ACBB-167B3DE29EAAQ34017814-82AD0D2B-A563-4BA4-B83D-F3FF77397F7CQ34084987-3014FB1E-FA9B-4D4E-A5E0-40C331FDD5F1Q34183191-CE9F09D9-A6C5-430F-A422-C6EC199AB574Q34208672-09D071F3-2971-49F5-AB6F-A14AC641E893Q34382067-F2873C24-1C99-475D-B12B-645DB05B372BQ34408879-FB7A9DBC-ADD7-4446-80CD-F799E980BB8AQ34509494-FBACBF0B-C5C9-4A20-AC7F-4637FD2FE8ADQ34647599-BCADBE29-3A90-43DE-A198-F4C8712D8511Q34685945-6F332E1D-37F4-4451-BC2E-29BDA509BC71Q35073559-E7BF51AD-7FF2-40AB-B2A7-F7FC9C1BAE88Q35259824-5BAA8785-257D-4D2A-B23F-C2364302D326Q35635637-475DFCEE-7131-45D3-A36E-81489E27629BQ35890599-4BA34D01-5028-4F47-A68D-492BE26AD8C5Q36301502-861EFCD3-26CD-44CF-9ACA-FBDE8EEAC558Q36445386-EF05BB8D-CCC0-44DF-9274-2BD5D4742666Q36740003-6BDA26C7-400A-4730-9C37-0E5E11FB8CB0Q36841719-F7701D88-B5EC-4CD6-9702-4AE9B70A5AEAQ37074608-88048164-BF33-400C-9C4B-133E5D741943Q37255008-A1347326-68C2-4B18-AC0E-35650715923CQ37278298-C34EB2FD-6A1E-4823-B514-7D0488279F85Q38132740-E8BB654D-4729-45FE-9D64-07F4FA31CA4AQ38543533-3A615F8E-52D5-4A7C-94F5-660523585D34Q39429039-B9488AEF-6997-420A-9008-7B9B756D3D1BQ41859437-6C87B76D-27A5-4370-AEDF-8DB7578985E8Q41883516-8E4775DF-4BA1-4005-B868-0434926C710FQ41921247-BF502B85-B635-4A1B-8E59-E5641ED8F6ADQ41989421-E1FFC566-A580-47E4-8316-3C8ABA88C6D0Q42142873-00D549FD-2A08-4708-B049-6DB755FEE2ECQ42210924-3AE59FA1-449B-4009-8FF2-4747592DF5D0Q42287932-619D82EB-E153-49C2-9BF6-0448407A849CQ42409548-B7BE2EA1-E941-4221-A309-D858D62F067AQ42590818-EE908725-A6E1-44A7-ADA4-96E54FEEC086Q42619923-743F5DE2-7820-4BBE-A53B-E28844FC05B7Q43071697-49509546-B6AB-4E74-B66F-C87FB6BEAF5C
P2860
Management of antiviral resistance in patients with chronic hepatitis B.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Management of antiviral resistance in patients with chronic hepatitis B.
@ast
Management of antiviral resistance in patients with chronic hepatitis B.
@en
type
label
Management of antiviral resistance in patients with chronic hepatitis B.
@ast
Management of antiviral resistance in patients with chronic hepatitis B.
@en
prefLabel
Management of antiviral resistance in patients with chronic hepatitis B.
@ast
Management of antiviral resistance in patients with chronic hepatitis B.
@en
P2093
P1433
P1476
Management of antiviral resistance in patients with chronic hepatitis B
@en
P2093
Angelos Hatzakis
David Mutimer
Emmet B Keeffe
Jenny Heathcote
Stephen Locarnini
T Jake Liang
P304
P577
2004-10-01T00:00:00Z